CD44 and neoplasm: Clinical studies suggest patients with CD44s-positive tumors may benefit from HA–irinotecan, while HA-based nanocarriers in CD44-overexpressing tumors enhance drug delivery, increase therapeutic efficacy with low cytotoxicity, inhibit tumor growth, and enable targeted chemotherapy [37,52].